com 110 111 Annual Report and Accounts for the year ended 30 June 2012 Stock Code: DPH Our Business Our Accounts Notes to the Consolidated Financial Statements continued 15.
Borrowings 2012 2011 2012 2011 000 000 000 000 Raw materials and consumables 7,732 5,170 Current liabilities: Work in progress 1,661 371 Bank loans 5,000 8,000 Finished goods and goods for resale 47,888 35,219 Finance lease obligations 695 502 57,281 40,760 Arrangement fees netted off 589 5,106 8,502 Non-current liabilities: 16.
Trade and Other Receivables Bank loans 115,757 55,746 2012 2011 Finance lease obligations 246 339 000 000 Arrangement fees netted off 1,957 Trade receivables 69,596 62,212 114,046 56,085 Other receivables 965 2,492 Total borrowings 119,152 64,587 Prepayments and accrued income 1,552 1,589 72,113 66,293 On 4 April 2012, the Group refinanced its existing bank facility, which gave rise to a loss on extinguishment of debt of 158,000.
The Groups revised borrowing facilities comprise a term loan of 55 million payable over 4 years, a 65 million 17.
Cash and Cash Equivalents revolving credit facility committed until 31 October 2016, an overdraft facility of 10 million currently unutilised renewable on 2012 2011 1 April 2013 and various finance lease obligations.
000 000 Cash at bank and in hand 32,435 30,496 At the year end, the Group had the following unutilised borrowing facilities: 18.
Trade and Other Payables 2012 2011 2012 2011 000 000 000 000 Bank overdraft facility 10,000 10,000 Trade payables 63,559 63,213 Revolving credit facility 254 Other payables 6,745 4,770 Derivative financial instruments 387 397 The term loan, revolving credit and overdraft facilities are secured by a fixed and floating charge on the assets of the Group.
Other taxation and social security 3,402 3,827 Interest is charged at 2.50% over LIBOR in respect of the term loan and revolving credit facility and 2.50% over base rate in Accruals and deferred income 5,770 2,352 respect of the overdraft facility.
No covenants have been breached during the year ended 30 June 2012.
79,863 74,559 The maturity of the bank loans and overdrafts is as follows: 19.
Current Tax Liabilities 2012 2011 2012 2011 000 000 000 000 Corporation tax payable 8,155 5,391 Payable: Within one year 5,000 8,000 Between one and two years 10,000 8,000 Between two and five years 105,757 47,746 Due after five years 120,757 63,746 21587-04 10 08 2012 Proof 3 21587-04 10 08 2012 Proof 3 Shareholder Directors Report Directors Report Information Our Accounts Our Governance Our Performance Our Business Dechra Pharmaceuticals PLC www.
com 112 113 Annual Report and Accounts for the year ended 30 June 2012 Stock Code: DPH Our Business Our Accounts Notes to the Consolidated Financial Statements continued 20.
Employee Benefit Obligations continued The minimum lease payments and the present value of minimum lease payments payable under finance lease obligations are: In valuing the liabilities of the pension scheme at 30 June 2012, mortality assumptions have been made as indicated below.
Present Value of The mortality assumption follows the AG Prognosetafel 2010-2060 mortality tables with an experience adjustment in line with Minimum Lease Minimum Lease the ES-P2 tables as published by the Dutch Alliance of Insurers.
Payments Payments The assumptions used by the Group are the best estimates chosen by the Directors from a range of possible actuarial 2012 2011 2012 2011 assumptions which, due to the timescale covered, may not necessarily be borne out in practice.
000 000 000 000 Within one year 730 543 695 502 2012 Between one and two years 217 343 210 335 000 Between two and five years 36 4 36 4 Total minimum lease payments 983 890 941 841 Present value of funded defined benefit obligations 2,801 Future finance charges 42 49 Fair value of scheme assets 2,438 Present value of lease obligations 941 841 941 841 Net pension scheme deficit 363 Further information on the interest profile of borrowings is shown in note 22.
Movements in Present Value of Defined Benefit Obligations 2012 21.
Employee Benefit Obligations 000 The Group sponsors defined benefit arrangements in certain countries, the most material being a defined benefit pension Defined benefit obligation at acquisition 2,745 plan in the Netherlands.
This is a funded career average pay arrangement, where pensionable salary is subject to a cap.
The Service cost 37 arrangement is financed through an insurance contract.
Interest cost 12 Employee contributions 7 The other defined benefit pension arrangements operated by the Company are unfunded: Jubilee awards of 61,000 for Defined benefit obligations at end of the period 2,801 employees in the Netherlands and Germany and early retirement plan provisions in Germany of 2,000 are recognised within other payables in the statement of financial position as at 30 June 2012.
Movements in Fair Value of Scheme Assets 2012 The pension cost relating to the defined benefit pension arrangement in the Netherlands is assessed in accordance with the 000 advice of an independent qualified actuary using the projected unit method.
Fair value of scheme assets at acquisition 2,404 Expected return on scheme assets 10 The major actuarial assumptions used by the actuary were: Additional charges 23 Employer contributions 40 2012 Employee contributions 7 Discount rate 4.60% Fair value of scheme assets at end of the period 2,438 Expected return on assets 4.60% Inflation assumption 1.90% Analysis of the Amount Charged to the Income Statement Salary growth 2.40% Rate of increase in accrued pensions of active members 1.90% 2012 Rate of increase in pensions in payment 0.00% 000 Rate of increase in pensions in deferment 0.00% Service cost 37 Expected return on assets 10 Interest on liabilities 12 Insurance charges 23 Net pension expense 62 21587-04 10 08 2012 Proof 3 21587-04 10 08 2012 Proof 3 Shareholder Directors Report Directors Report Information Our Accounts Our Governance Our Performance Our Business Dechra Pharmaceuticals PLC www.
com 114 115 Annual Report and Accounts for the year ended 30 June 2012 Stock Code: DPH Our Business Our Accounts Notes to the Consolidated Financial Statements continued 21.
Financial Instruments and Related Disclosures Scheme Assets The Groups financial instruments comprise cash deposits, bank loans and overdrafts, finance lease obligations, derivatives The Groups defined benefit pension scheme in the Netherlands is financed through an insurance contract.
Under this contract, used for hedging purposes and trade receivables and payables.
a market price for the assets in respect of this insurance contract is not available.
In accordance with IAS 19 for such insurance policies, an asset value has been calculated by discounting expected future cash flows.
The discount rate used for this Treasury Policy calculation reflects the risk associated with the scheme assets and the maturity or expected disposal date of those assets.
The Group reports in Sterling and pays dividends out of Sterling profits.
The role of the Groups treasury activities is to manage and monitor the Groups external and internal funding requirements and financial risks in support of the Groups corporate The fair value of the schemes assets is as follows: activities.
2012 000 Treasury activities are governed by policies and procedures approved by the Board of Directors.
Discount rate used to value assets 4.60% The Group uses a variety of financial instruments, including derivatives, to finance its operations and to manage market risks from Total fair value of assets 2,438 these operations.
Derivatives, principally comprising forward foreign currency contracts, foreign currency options and interest rate Actual return on scheme assets 10 swaps, are used to hedge against changes in foreign currencies and interest rates.
The long term rate of return on pension plan assets is determined by aggregating the expected return for each asset class over The Group does not hold or issue derivative financial instruments for speculative purposes and the Groups treasury policy the strategic asset allocation as at 30 June 2012.
This rate of return is then adjusted for any expected profit sharing based on specifically prohibits such activity.
All transactions in financial instruments are undertaken to manage the risks arising from market related returns on notional loans.
underlying business activities, not for speculation.
The schemes assets do not include any of the Groups own financial instruments or any property occupied by or other assets Capital Management used by the Group.
The capital structure of the Group consists of net borrowings and Shareholders equity.
At 30 June 2012, net borrowings were 86.7 million, whilst Shareholders equity was 153.7 million.
The employer contributions expected to be paid into the scheme for the next financial period amount to 480,000.
The Group maintains a strong capital base so as to maintain investors, creditors and market confidence and to sustain future History of Amounts in the Current Period development of the business.
The Group monitors both the demographic spread of Shareholders, as well as the return on 2012 capital, which the Group defines as total Shareholder return.
000 Present value of funded defined benefit obligations 2,801 The Group manages its capital structure to maintain a prudent balance between debt and equity that allows sufficient Fair value of scheme assets 2,438 headroom to finance the Groups product development programme and appropriate acquisitions.
Current economic conditions Deficit in the scheme 363 mean that it is more difficult and expensive to obtain finance via borrowings.
The Group operates globally, primarily through subsidiary companies established in the markets in which the Group trades.
The Groups operating subsidiaries are generally cash generative and none are subject to externally imposed capital requirements.
There are financial covenants associated with the Groups borrowings which are cash flow cover, interest cover, net debt to EBITDA and consolidated net worth.
The Group comfortably complied with these covenants in 2012 and 2011.
There were no changes in the Groups approach to capital management during the year.
Operating cash flow is used to fund investment in the development of new products as well as to make the routine outflows of capital expenditure, tax, dividends and repayment of maturing debt.
The Groups policy is to maintain borrowing facilities centrally which are then used to finance the Groups operating subsidiaries, either by way of equity investments or loans.
21587-04 10 08 2012 Proof 3 21587-04 10 08 2012 Proof 3 Shareholder Directors Report Directors Report Information Our Accounts Our Governance Our Performance Our Business Dechra Pharmaceuticals PLC www.
com 116 117 Annual Report and Accounts for the year ended 30 June 2012 Stock Code: DPH Our Business Our Accounts Notes to the Consolidated Financial Statements continued 22.
Financial Instruments and Related Disclosures continued 22.
Financial Instruments and Related Disclosures continued Financial Risk Management Credit Risk The Group has exposure to the following risks from its use of financial instruments: Credit risk is the risk of financial loss to the Group if a customer or counterparty to a financial instrument fails to meet its contractual obligations.
liquidity risk market risk The Group considers its maximum credit risk to be 102,996,000 2011: 95,200,000 which is the total carrying value of the credit risk Groups financial assets.
This note presents information about the Groups exposure to each of the above risks, and the Groups objectives, policies and Cash is only deposited with highly rated banks.
processes for measuring and managing risk.
The Group offers trade credit to customers in the normal course of business.
Trade and bank references are obtained prior to Liquidity Risk extending credit.
The financial statements of corporate customers are monitored on a regular basis.
Liquidity risk is the risk that the Group will not have sufficient funds to meet liabilities as they fall due.
Cash forecasts identifying the liquidity requirements of the Group are produced quarterly.
These are reviewed to ensure sufficient financial headroom The principal customers of the Services segment are UK veterinary practices.
The customer base is diverse and, with the exists for at least a 12 month period.
exception of the largest corporate accounts, the failure of a single customer would not have a material adverse impact on the Groups financial results.
The Group manages its funding requirements through the following lines of credit: The principal customers of the Pharmaceuticals segments are European and US wholesalers.
The failure of a large wholesaler 55 million term loan could have a material adverse impact on the Groups financial results.
65 million revolving credit facility 10 million working capital facility The largest customer of the Group accounted for approximately 13.4% of gross trade receivables at 30 June 2012 2011: various finance leases 13.1%.
No customer accounted for more than 10% of total Group revenues.
The Groups undrawn borrowing facilities at 30 June 2012 are detailed in note 20.
Receivables are written off against the impairment provision when management considers the debt to be no longer recoverable.
Market Risk Market risk is the risk that changes in market prices, such as foreign exchange rates or interest rates, will affect the Groups Fair Value of Financial Assets and Liabilities income or the value of its holding of financial instruments.
The following table presents the carrying amounts and the fair values of the Groups financial assets and liabilities at 30 June 2012 and 30 June 2011.
Interest Rate Risk Management The majority of the Groups borrowings bear interest at floating rates linked to base rate or LIBOR and are consequently The following assumptions were used to estimate the fair values: exposed to cash flow interest rate risk.
Cash and cash equivalents approximates to the carrying amount.
The Group has hedged interest rate risk on a proportion of its term loan and revolving credit facility by means of an interest Forward exchange contracts based on market price and exchange rates at the balance sheet date.
rate swap arrangement whereby the Groups exposure to fluctuations in LIBOR is fixed at a rate of 1.6875% on the term loan Interest rate swaps based upon the amount that the Group would receive or pay to terminate the instrument at the and 1.185% on the revolving credit facility.
The amount of the term loan and revolving credit outstanding at 30 June 2012 was balance sheet date, being the market price of the instrument.
The hedge is in place until 31 December 2013 and the amount hedged matches the repayment profile of the Receivables and payables approximates to the carrying amount.
Bank loans and overdrafts based upon discounted cash flows using discount rates based upon facility rates renegotiated after the 30 June 2011 year end.
Foreign Exchange Risk Management Finance lease obligations based upon discounted cash flows using discount rates based upon the Groups cost of Foreign currency transaction exposure arising on normal trade flows is not hedged.
The Group matches receipts and payments borrowing at the balance sheet date.
in the relevant foreign currencies as far as possible.
To this end, bank accounts are maintained for all the major currencies in which the Group trades.
Translational exposure in converting the income statements of foreign subsidiaries into the Groups presentational currency of Sterling is not hedged.
The Group hedges selectively expected currency cash flows outside normal trading activities, principally using foreign currency options.
com 118 119 Annual Report and Accounts for the year ended 30 June 2012 Stock Code: DPH Our Business Our Accounts Notes to the Consolidated Financial Statements continued 22.
Financial Instruments and Related Disclosures continued Analysis of Financial Instruments Credit Risk Overdue Financial Assets The financial instruments of the Group are analysed as follows: The following table shows financial assets which are overdue and for which no impairment provision has been made: 2012 2011 2012 2011 Carrying Fair 000 000 Carrying Fair value value value value Overdue by: 000 000 000 000 Up to one month 5,810 3,731 Financial assets Between one and two months 983 1,276 Cash and cash equivalents 32,435 32,435 30,496 30,496 Between two and three months 644 1,005 32,435 32,435 30,496 30,496 Over three months 2,649 1,764 Loans and receivables 10,086 7,776 trade receivables 69,596 69,596 62,212 62,212 other receivables 965 965 2,492 2,492 The movement in the impairment provision was as follows: 70,561 70,561 64,704 64,704 Total financial assets 102,996 102,996 95,200 95,200 2012 2011 Financial liabilities 000 000 Bank loans and overdrafts 120,757 120,757 63,746 62,026 At start of period 2,911 2,383 Held for trading financial liabilities Impairment provision recognised 231 716 derivatives designated as hedges 387 387 397 397 Impairment provision utilised 265 188 Finance lease liabilities 941 938 841 799 At end of period 2,877 2,911 Trade payables 63,559 63,559 63,213 63,213 Other payables 13,222 13,222 7,122 7,122 Liquidity Risk Contracted Cash Flows of Financial Liabilities Deferred and contingent consideration 13,863 13,863 14,055 14,055 The following table shows the cash flow commitments of the Group in respect of financial liabilities excluding derivatives at Total financial liabilities 212,729 212,726 149,374 147,612 30 June 2012 and 30 June 2011.
Where interest is at floating rates, the future interest payments have been estimated using Net financial liabilities 109,733 109,730 54,174 52,412 current interest rates: Fair Value Hierarchy Deferred and Bank Loans Trade and The table below analyses financial instruments carried at fair value, by valuation method.
The different levels have been defined Contingent and Finance other as follows: Consideration Overdrafts Leases payables Total At 30 June 2012 000 000 000 000 000 Level 1 quoted prices unadjusted in active market for identical assets or liabilities.
Carrying value 13,863 118,211 941 76,781 209,796 Level 2 inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly Arrangement fees netted off 2,546 2,546 i. e. as prices or indirectly i. e. derived from prices.
Future interest 467 6,056 42 6,565 Level 3 inputs for the asset or liability that are not based on observable market data unobservable inputs.
Total committed cash flow 14,330 126,813 983 76,781 218,907 Payable: Level 1 Level 2 Level 3 Total Within 6 months 756 365 76,781 77,902 30 June 2012 000 000 000 000 Between 6 months and 1 year 10,336 6,760 365 17,461 Derivative financial liabilities 387 387 Between 1 and 2 years 11,666 217 11,883 Deferred and contingent consideration 13,863 13,863 Between 2 and 3 years 3,994 11,315 36 15,345 Total 387 13,863 14,250 Between 3 and 4 years 15,921 15,921 Between 4 and 5 years 80,395 80,395 Level 1 Level 2 Level 3 Total Over 5 years 30 June 2011 000 000 000 000 14,330 126,813 983 76,781 218,907 Derivative financial liabilities 397 397 Deferred and contingent consideration 14,055 14,055 Total 397 14,055 14,452 Movements in deferred and contingent consideration consists of a 0.5 million payment made under the terms of the Genitrix acquisition and a 0.3 million increase in relation to the DermaPet acquisition due to unwinding of discount.
com 120 121 Annual Report and Accounts for the year ended 30 June 2012 Stock Code: DPH Our Business Our Accounts Notes to the Consolidated Financial Statements continued 22.
Financial Instruments and Related Disclosures continued Deferred and Bank Loans Trade and Foreign Currency Exposure Contingent and Finance other The Sterling equivalents of financial assets and liabilities denominated in foreign currencies at 30 June 2012 and Consideration Overdrafts Leases payables Total 30 June 2011 were: At 30 June 2011 000 000 000 000 000 Danish US Carrying value 14,055 63,746 841 70,335 148,977 Krone Euro Dollar Other Future interest 839 2,825 49 3,713 At 30 June 2012 000 000 000 000 Total committed cash flow 14,894 66,571 890 70,335 152,690 Payable: Financial assets Within 6 months 4,532 271 70,335 75,138 Trade receivables 6,666 9,902 4,019 2,222 Between 6 months and 1 year 500 4,573 271 5,344 Other receivables 147 284 20 73 Cash balances 2,766 4,900 7,372 3,042 Between 1 and 2 years 10,096 8,932 344 19,372 Other financial assets 242 49 171 Between 2 and 3 years 12,645 4 12,649 9,821 15,135 11,411 5,508 Between 3 and 4 years 4,298 35,889 40,187 Financial liabilities Between 4 and 5 years Bank loans and overdrafts 17,264 28,675 Over 5 years Finance leases 248 14,894 66,571 890 70,335 152,690 Trade payables 1,794 2,333 1,210 142 Other financial liabilities 3,921 1,902 1,669 The contractual undiscounted cash flows in respect of derivative financial instruments are as follows: 5,715 21,747 29,885 1,811 Net balance sheet exposure 4,106 6,612 18,474 3,697 2012 2011 Receivables Payables Receivables Payables 000 000 000 000 Danish US Due: Krone Euro Dollar Other Within 6 months 81 108 At 30 June 2011 000 000 000 000 Between 6 months and 1 year 94 114 Financial assets Between 1 and 2 years 212 175 Trade receivables 1,877 3,514 4,320 5,858 387 397 Other receivables 168 30 232 Cash balances 1,675 786 1,163 2,622 Other financial assets 480 103 133 The Group has a contractual obligation to pay 81,000 2011: 108,000 under its interest rate swap arrangement covering 4,200 4,433 5,483 8,845 the period from 29 June to 28 September 2012.
Financial liabilities Bank loans 3,997 27,746 With the exception of the above disclosed, there are no other assets that have been impaired during the year.
Finance leases 406 Trade payables 3,225 1,141 167 284 Derivatives 3,286 1,479 1,090 6,511 7,023 27,913 1,374 Net balance sheet exposure 2,311 2,590 22,430 7,471 21587-04 10 08 2012 Proof 3 21587-04 10 08 2012 Proof 3 Shareholder Directors Report Directors Report Information Our Accounts Our Governance Our Performance Our Business Dechra Pharmaceuticals PLC www.
com 122 123 Annual Report and Accounts for the year ended 30 June 2012 Stock Code: DPH Our Business Our Accounts Notes to the Consolidated Financial Statements continued 22.
Financial Instruments and Related Disclosures continued 24.
Share-based Payments Sensitivity Analysis During the year, the Company operated the Unapproved Share Option Scheme, the Approved Share Option Scheme, the Long Interest Rate Risk Term Incentive Plan and the Save As You Earn SAYE Share Option Scheme as described below: A 2.0% increase in interest rates compared to those ruling at 30 June 2012 would reduce Group profit before taxation and equity by 168,000 2011: 281,000.
Unapproved and Approved Share Option Schemes Under these Schemes, options are granted to certain Executives and employees of the Group excluding Executive Directors Foreign Currency Risk to purchase shares in the Company at a price fixed at the average market value over the three days prior to the date of grant.
The Group has significant cash flows and net financial assets and liabilities in Danish Krone, US Dollar and Euro.
For the options to vest, there must be an increase in earnings per share of at least 12% above the growth in the UK Retail The following table shows the impact on the Groups profit before taxation and net assets of a 10% appreciation of Sterling Prices Index RPI over a three year period.
Once vested, options must be exercised within ten years of the date of grant.
against each of these currencies: Profit Long Term Incentive Plan before Net Under this plan vesting is dependent firstly on an earnings per share target.
No awards will vest unless underlying diluted taxation assets earnings per share has grown by at least 3% per annum above the retail prices index over the three year measurement period.
000 000 Provided this condition is met, then the number of shares that vest depends on the Companys TSR performance against the FTSE Small Cap Index over the three year measurement period.
One hundred per cent of the shares vest if the Company Danish Krone 4,077 5,925 achieves an upper quartile performance, 25% of the shares vest at median performance and awards vest on a straight-line US Dollar 36 323 basis for performance in between.
No shares vest if performance is below median.
Euro 210 1,989 SAYE Option Scheme Hedges This Scheme is open to all UK employees.
Participants save a fixed amount of up to 250 per month for either three, five Cash Flow Hedges or seven years and are then able to use these savings to buy shares in the Company at a price fixed at a 20% discount to The Group has entered into an interest rate swap on the term loan of 55.0 million and the revolving credit facility of the market value at the start of the savings period.
The SAYE options must ordinarily be exercised within six months of the 65.0 million.
The Group has designated this a cash flow hedge.
The risk being hedged is the variability of cash flows arising completion of the relevant savings period.
The exercise of these options is not subject to any performance criteria.
from movements in interest rates.
No ineffectiveness arose on the hedge.
The hedge is in place until 30 September 2013.
The amounts recognised in equity are recycled to the income statement to offset gains and losses in the period in which the cash flows occurs.
The amount recognised in equity in the year ended 30 June 2012 was a liability of 286,000 including an income tax credit of 101,000 2011: 294,000 including an income tax credit of 103,000.
Share Capital Ordinary shares of 1p each 2012 2011 000 No.
Allotted, called up and fully paid at start of year 664 66,449,659 661 66,090,075 Rights issue 201 20,040,653 New shares issued 4 379,864 3 359,584 Allotted, called up and fully paid at end of year 869 86,870,176 664 66,449,659 The Companies Act 2006 abolishes the requirement for a company to have an authorised share capital.
At the 2009 Annual General Meeting the Shareholders approved a resolution whereby all provisions relating to the Companys authorised share capital were removed from the Companys constitutional documents.
During the year 379,864 new ordinary shares of 1p 2011: 359,584 new ordinary shares of 1p were issued following the exercise of options under the Long Term Incentive Plan, and the Approved, Unapproved and SAYE Share Options Schemes.
The holders of ordinary shares are entitled to receive dividends as declared or approved at General Meetings from time to time and are entitled to one vote per share at such meetings of the Company.
The Company issued 20,040,653 shares of 1p each by way of a 3 for 10 Rights Issue at an issue price of 300p per share on 16 May 2012.
The rights issue generated net proceeds of 58,835,110 after costs of 1,286,849.
The issue price represented a discount of 35.3% to the closing price of 464p per share on 4 April 2012, being the last business day before the announcement of the Rights Issue.
com 124 125 Annual Report and Accounts for the year ended 30 June 2012 Stock Code: DPH Our Business Our Accounts Notes to the Consolidated Financial Statements continued 24.
Total share options exercisable at 30 June 2011 are 240,154.
Total share options exercisable at 30 June 2012 are 296,135.
The weighted average exercise price of options eligible to be exercised at 30 June 2012 was 302.5p 2011: 293.2p.
For options exercised during the year, the weighted average market price at the date of exercise was 461p 2011: 503p.
The weighted average remaining contractual lives of options outstanding at the consolidated statement of financial position date was four years 2011: four years.
com 126 127 Annual Report and Accounts for the year ended 30 June 2012 Stock Code: DPH Our Business Our Accounts Notes to the Consolidated Financial Statements continued 24.
Share-based Payments continued Outstanding options on all Long Term Incentive Plan, Approved and Unapproved plans prior to 30 June 2009 were exercisable Save As You Earn Option Scheme at 30 June 2012.
Date of grant 17 10 11 13 12 10 Number of shares awarded 97,486 112,743 No options issued under SAYE plans were exercisable at 30 June 2012.
Share price at date of grant 478p 507p Exercise price 398p 409p The fair values for shares granted under the Unapproved, Approved and SAYE Option Schemes have been calculated using the Expected life Black-Scholes option pricing model.
The fair values of shares awarded under the Long Term Incentive Plan have been calculated three year scheme 3.25 years 3.25 years using a Monte Carlo simulation model which takes into account the market-based performance conditions attaching to those five year scheme 5.25 years 5.25 years shares.
seven year scheme 7.25 years 7.25 years Risk-free rate The assumptions used in calculating fair value are as follows: three year scheme 0.98% 1.46% five year scheme 1.58% 2.24% Long Term Incentive Plan seven year scheme 2.11% 2.90% Date of grant 07 09 11 22 12 10 Volatility 34% 36% Number of shares awarded 279,263 235,841 Dividend yield 2.53% 2.07% Share price at date of grant 455.5p 514.00p Fair value per share Exercise price Nil Nil three year scheme 140p 165p Expected life 3 years 3 years five year scheme 147p 181p Risk-free rate 0.85% 1.60% seven year scheme 161p 201p Volatility 38% 39% Dividend yield 2.66% 2.04% Expected volatility was determined by calculating the historical volatility of the Groups share price over its entire trading history.
Fair value per share 276p 322p National Insurance contributions are payable by the Company in respect of some of the share-based payments.
These Unapproved and Approved Share Option Schemes contributions are payable on the date of exercise based on the intrinsic value of the share-based payments and are therefore Date of grant 28 02 11 treated as cash settled awards.
The Group had an accrual at 30 June 2012 of 73,000 2011: 229,000, of which 18,000 Number of shares awarded 84,000 2011: 15,000 related to vested options.
The total charge to the Income Statement in respect of share-based payments was: Share price at date of grant 507.5p Exercise price 503p 2012 2011 000 000 Expected life 5 years Risk-free rate 2.65% Equity settled share-based transactions 1,001 830 Volatility 36% Cash settled share-based transactions 24 118 Dividend yield 2.07% 977 948 Fair value per share 149p The above charge to the Income Statement is included within administrative expenses.
com 128 129 Annual Report and Accounts for the year ended 30 June 2012 Stock Code: DPH Our Business Our Accounts Notes to the Consolidated Financial Statements continued 25.
Acquisitions 2012 2011 Acquisition of Eurovet Animal Health B. V. 000 000 On 23 May 2012, the Group acquired 100% of the share capital of Eurovet Animal Health B. V. obtaining control of Eurovet.
Eurovet is a veterinary pharmaceuticals business based in mainland Europe with its head office, manufacturing facility, research Bank loans 118,211 63,746 and development team and central sales and marketing office located in the Netherlands.
Additionally, it has operations in Finance leases and hire purchase contracts 941 841 Germany, Belgium, Denmark and the United Kingdom.
Cash and cash equivalents 32,435 30,496 Net borrowings 86,717 34,091 It has highly complementary products, geographies, manufacturing competencies and is similar in structure to Dechra Veterinary Products.
Operating Leases At the balance sheet date the Group had outstanding commitments for future minimum rentals payable under non-cancellable Provisional operating leases as follows: Book value fair value 000 000 Land and buildings Other assets Total Recognised amounts of identifiable assets acquired and liabilities assumed 2012 2011 2012 2011 2012 2011 Identifiable assets 000 000 000 000 000 000 Property, plant and equipment 9,454 9,454 Within one year 1,301 1,219 2,279 1,278 3,580 2,497 Trade and other receivables 6,600 6,596 Between one and five years 3,300 4,062 2,414 1,234 5,714 5,296 Inventory 12,795 12,507 In five years or more 2,927 3,472 2,927 3,472 Cash and cash equivalents 3,989 3,989 7,528 8,753 4,693 2,512 12,221 11,265 Indentifiable intangible assets 14,620 78,703 Identifiable liabilities The Group leases properties, plant, machinery and vehicles for operational purposes.
Property leases vary in length up to a Trade and other payables 8,354 8,825 period of 25 years.
Plant, machinery and vehicle leases typically run for periods of up to 5 years.
Employee benefit obligations 341 341 Current tax 1,041 1,690 27.
Foreign Exchange Rates Deferred tax 858 20,531 The following exchange rates have been used in the translation of the results of foreign operations.
Net identifiable assets 36,864 79,862 Goodwill 36,348 Closing Closing Total consideration 116,210 rate rate Satisfied by: at 30 June Average at 30 June Cash 116,210 2011 rate 2012 Total consideration transferred 116,210 Danish Krone 8.256 8.7165 9.21 Net cash outflow arising on acquisition Euro 1.1070 1.1716 1.2389 Cash consideration 116,210 US Dollar 1.6073 1.5686 1.5681 Less: cash and cash equivalent balances acquired 3,989 112,221 The fair values shown above are provisional and may be amended if information not currently available comes to light.
The fair value of the financial assets includes trade receivables with a fair value of 5,669,000.
The provisional fair value adjustments principally relate to harmonisation with Group IFRS accounting policies, including the application of fair values on acquisition, principally the recognition of product rights in accordance with IFRS 3.
The goodwill of 36,348,000 arising from the acquisition consists of the synergies, assembled workforce, technical expertise and the increased geographical presence in Germany and the Netherlands.
None of the goodwill is expected to be deductible for income tax purposes.
Acquisition related costs included in operating expenses amounted to 2,315,000.
Eurovets results are reported within the European Pharmaceuticals segment.
Eurovet contributed 7,127,000 revenue and 852,000 to the Groups underlying pre-tax profit for the period between the date of acquisition and the balance sheet date.
If the acquisition of Eurovet had been completed on the first day of the financial year, Group revenues for the period would have been 500,775,000 and the Group underlying pre-tax profit would have been 40,898,000.
com 130 131 Annual Report and Accounts for the year ended 30 June 2012 Stock Code: DPH Our Business Our Accounts Notes to the Consolidated Financial Statements continued 28.
Acquisitions continued Acquisition of Genitrix Limited Acquisition of DermaPet Inc. On 1 December 2010, the Group acquired 100% of the share capital of Genitrix Limited.
The acquisition of Genitrix Limited, On 22 October 2010, the Group acquired 100% of the share capital of DermaPet Inc. a Florida based business which a veterinary pharmaceuticals company based in Billingshurst, UK, is consistent with our strategy to grow our domestic and develops and markets a range of dermatological preparations, including shampoos, conditioners and ear products, for the US international pharmaceutical business.
and overseas companion animal markets.
These veterinary products are marketed and distributed through the same channels as Dechras current US product portfolio.
Book value Fair value 000 000 The acquisition of DermaPet Inc. increases Dechras US presence and complements its EU range in this key strategic therapeutic category.
Recognised amounts of identifiable assets acquired and liabilities assumed Identifiable assets Book value Fair value Intangible assets 184 184 000 000 Property, plant and equipment 27 23 Trade and other receivables 326 326 Recognised amounts of identifiable assets acquired and liabilities assumed Inventory 217 217 Identifiable assets Cash and cash equivalents 59 59 Identifiable assets Trade and other receivables 1,084 1,084 Identifiable intangible assets 5,596 Inventory 384 384 Identifiable liabilities Identifiable intangible assets 38,909 Trade and other payables 318 318 Deferred tax liabilities 36 1,546 Identifiable liabilities Net identifiable assets 459 4,541 Overdraft 1 1 Goodwill 1,845 Trade and other payables 216 216 Total consideration 6,386 Net identifiable assets 1,251 40,160 Satisfied by: Goodwill 326 Cash 5,586 Total consideration 40,486 Contingent consideration arrangement 800 Satisfied by: Cash 27,519 Total consideration transferred 6,386 Deferred consideration 1,163 Net cash outflow arising on acquisition Contingent consideration arrangement 11,804 Cash consideration 5,586 Less: cash and cash equivalent balances acquired 59 Total consideration transferred 40,486 5,527 Net cash outflow arising on acquisition Cash consideration 27,519 Add: bank overdraft 1 The fair value of the financial assets includes trade receivables with a fair value of 290,000.
The fair value adjustment in 27,520 relation to intangible assets recognises product rights in accordance with IFRS 3.
The goodwill of 1,845,000 arising from the acquisition consists of the assembled workforce and associated technical The fair value of the financial assets includes trade receivables with a fair value of 1,076,000.
The fair value adjustment in expertise.
relation to intangible assets recognises product rights in accordance with IFRS 3.
The contingent consideration arrangement, which has been reassessed between the date of acquisition and the year end The goodwill of 326,000 arising from the acquisition consists of the assembled workforce and increased geographical and remains unadjusted, requires payment of 800,000 to be paid on the achievement of specific milestones.
An amount of presence in the US.
The goodwill and identified intangibles are expected to be deductible for income tax purposes.
500,000 was paid during the year ended 30 June 2012 leaving a remaining potential payment of 300,000.
The deferred consideration arrangement requires payments of US$1,000,000 to be paid on the second and fourth Acquisition related costs included in non-underlying operating expenses amounted to 108,000. anniversaries of the completion date.
The contingent consideration arrangement requires that if DermaPet Inc. achieves revenue in excess of US$15,000,000 in any rolling 12 month period commencing on the first anniversary of completion and ending on the sixth anniversary of completion, contingent consideration of US$15,000,000, which has been reassessed between the date of acquisition and the year end and remains unadjusted, will become payable.
If revenue on the same criteria exceeds US$20,000,000, a further US$5,000,000 will become due.
Acquisition related costs included in non-underlying operating expenses amounted to 585,000.
com 132 133 Annual Report and Accounts for the year ended 30 June 2012 Stock Code: DPH Our Business Our Accounts Notes to the Consolidated Financial Statements Company Balance Sheet At 30 June 2012 continued 29.
Related Party Transactions 2012 2011 Subsidiaries Note 000 000 The Groups ultimate Parent Company is Dechra Pharmaceuticals PLC.
A listing of all principal subsidiaries is shown within the Fixed assets financial statements of the Company on page 141.
Investments iii 251,104 132,119 Intangible assets iv 4,901 Transactions with Key Management Personnel 256,005 132,119 The details of the remuneration, Long Term Incentive Plans, shareholdings, share options and pension entitlements of individual Current assets Directors are included in the Directors Remuneration Report on pages 59 to 70.
The remuneration of key management is Debtors includes amounts falling due after more than one year of 571,000 disclosed in note 7.
Off Balance Sheet Arrangements 22,358 39,875 The Group has no off balance sheet arrangements to disclose as required by S410A of the Companies Act 2006.
Creditors: amounts falling due within one year vi 35,916 43,866 Net current liabilities 13,558 3,991 Total assets less current liabilities 242,447 128,128 Creditors: amounts falling due after more than one year vi 113,800 55,746 Net assets 128,647 72,382 Capital and reserves Called up share capital ix 869 664 Share premium account x 122,642 63,559 Hedging reserve x 286 294 Profit and loss account x 5,422 8,453 Total equity Shareholders funds 128,647 72,382 The financial statements were approved by the Board of Directors on 4 September 2012 and are signed on its behalf by: Ian Page Simon Evans Chief Executive Group Finance Director 4 September 2012 4 September 2012 Company number: 3369634 21587-04 10 08 2012 Proof 3 21587-04 10 08 2012 Proof 3 Shareholder Directors Report Directors Report Information Our Accounts Our Governance Our Performance Our Business
